Reason ferritin in low in body 23 y old girl its circumstances

Reading File
Finding Sources
Searching the Web

causes of low ferritin young women 23 year old iron deficiency circumstances

Searching PubMed

ferritin iron deficiency young women causes

Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Searching Images

iron deficiency anemia low ferritin causes pathophysiology diagram

A multi-panel pathophysiology infographic illustrating the main causes of acquired sideroblastic anemia through mitochondrial dysfunction. The central diagram depicts an erythroblast surrounded by three key impaired processes: Heme biosynthesis, Mitochondrial protein synthesis, and Fe/S (iron-sulfur) cluster biosynthesis. Ten surrounding panels detail specific etiologies including Hypothermia, SF3B1 mutation (Myelodysplastic Syndrome), Alcohol, Lead intoxication, Isoniazid, Copper deficiency/Zinc excess, Pyrazinamide, Pyridoxine (Vitamin B6) deficiency, Linezolid, and Chloramphenicol. Each panel uses molecular models to show specific inhibitory sites: for example, the inhibition of ALA-synthase by lead and vitamin B6 deficiency, or the disruption of the mitochondrial ribosome (30S and 50S subunits) by antibiotics like linezolid. The visual highlights how diverse toxic, nutritional, and genetic factors converge on mitochondrial metabolism, leading to iron overload in erythroblasts and the subsequent formation of ring sideroblasts.

A multi-panel pathophysiology infographic illustrating the main causes of acquired sideroblastic anemia through mitochondrial dysfunction. The central diagram depicts an erythroblast surrounded by three key impaired processes: Heme biosynthesis, Mitochondrial protein synthesis, and Fe/S (iron-sulfur) cluster biosynthesis. Ten surrounding panels detail specific etiologies including Hypothermia, SF3B1 mutation (Myelodysplastic Syndrome), Alcohol, Lead intoxication, Isoniazid, Copper deficiency/Zinc excess, Pyrazinamide, Pyridoxine (Vitamin B6) deficiency, Linezolid, and Chloramphenicol. Each panel uses molecular models to show specific inhibitory sites: for example, the inhibition of ALA-synthase by lead and vitamin B6 deficiency, or the disruption of the mitochondrial ribosome (30S and 50S subunits) by antibiotics like linezolid. The visual highlights how diverse toxic, nutritional, and genetic factors converge on mitochondrial metabolism, leading to iron overload in erythroblasts and the subsequent formation of ring sideroblasts.

This pathophysiology diagram illustrates the multifactorial causes and consequences of anemia in patients with heart failure (HF) and a left ventricular assist device (LVAD). The top section identifies contributors to anemia, including chronic gastrointestinal (GI) bleeding secondary to aspirin use, systemic anticoagulation, arteriovenous (AV) malformations, and von Willebrand disease. Other contributing factors shown are uremic gastritis, iron (Fe2+) malabsorption, and persistent right ventricular failure. Central to the diagram is the manifestation of anemia (defined as Hemoglobin < 12 g/dL), which correlates with elevated creatinine, decreased albumin, and increased mortality. The diagram also highlights therapeutic interventions such as erythropoiesis-stimulating agents (ESAs), aspirin-free antithrombotic management, omega-3 fatty acids, and low-intensity anticoagulation. Successful therapy is depicted as leading to normal red blood cell (RBC) counts, resolution of heart failure symptoms, and reduced mortality. The role of erythropoietin (EPO) is also noted in the context of LVAD-related anemia management.

This pathophysiology diagram illustrates the multifactorial causes and consequences of anemia in patients with heart failure (HF) and a left ventricular assist device (LVAD). The top section identifies contributors to anemia, including chronic gastrointestinal (GI) bleeding secondary to aspirin use, systemic anticoagulation, arteriovenous (AV) malformations, and von Willebrand disease. Other contributing factors shown are uremic gastritis, iron (Fe2+) malabsorption, and persistent right ventricular failure. Central to the diagram is the manifestation of anemia (defined as Hemoglobin < 12 g/dL), which correlates with elevated creatinine, decreased albumin, and increased mortality. The diagram also highlights therapeutic interventions such as erythropoiesis-stimulating agents (ESAs), aspirin-free antithrombotic management, omega-3 fatty acids, and low-intensity anticoagulation. Successful therapy is depicted as leading to normal red blood cell (RBC) counts, resolution of heart failure symptoms, and reduced mortality. The role of erythropoietin (EPO) is also noted in the context of LVAD-related anemia management.

This pathophysiology diagram illustrates the relationship between iron metabolism, macrophage polarization, and tumor growth within the tumor microenvironment (TME). A central cellular cluster depicts cancer cells (light orange), M1 macrophages (light blue, smooth), and M2 macrophages (purple, spiky). A vertical gradient represents iron concentration, influenced by 'Tumor iron influx' (bottom, associated with nanoparticles and anti-CD47) and 'Tumor iron efflux' (top, associated with chelation and anti-CSF1R). The diagram categorizes the TME into three metabolic regimes. 1) Low iron: favors M2 macrophages, characterized by increased ferroportin, lipocalin 2, and transferrin receptor but reduced ferritin, leading to reduced tumor growth. 2) Intermediate iron: characterized by 'iron-addicted' cancer cells with low ferroportin and high levels of ferritin, lipocalin 2, and transferrin receptor, which promotes tumor growth. 3) High iron: favors M1 macrophages, characterized by increased ferritin and reduced ferroportin, lipocalin 2, and transferrin receptor, resulting in reduced tumor growth. This educational infographic demonstrates how iron availability modulates immune cell phenotype and clinical outcomes in oncology.

This pathophysiology diagram illustrates the relationship between iron metabolism, macrophage polarization, and tumor growth within the tumor microenvironment (TME). A central cellular cluster depicts cancer cells (light orange), M1 macrophages (light blue, smooth), and M2 macrophages (purple, spiky). A vertical gradient represents iron concentration, influenced by 'Tumor iron influx' (bottom, associated with nanoparticles and anti-CD47) and 'Tumor iron efflux' (top, associated with chelation and anti-CSF1R). The diagram categorizes the TME into three metabolic regimes. 1) Low iron: favors M2 macrophages, characterized by increased ferroportin, lipocalin 2, and transferrin receptor but reduced ferritin, leading to reduced tumor growth. 2) Intermediate iron: characterized by 'iron-addicted' cancer cells with low ferroportin and high levels of ferritin, lipocalin 2, and transferrin receptor, which promotes tumor growth. 3) High iron: favors M1 macrophages, characterized by increased ferritin and reduced ferroportin, lipocalin 2, and transferrin receptor, resulting in reduced tumor growth. This educational infographic demonstrates how iron availability modulates immune cell phenotype and clinical outcomes in oncology.

I now have comprehensive information from authoritative sources. Here is a thorough answer:

Why Is Ferritin Low in a 23-Year-Old Woman?

Ferritin is the body's primary iron storage protein - a low serum ferritin is the most sensitive and specific indicator of depleted iron stores, even before anemia develops. In a 23-year-old woman, there are several well-defined circumstances that lead to this, categorized below.

What Is "Low" Ferritin?

  • Normal range for women: 12-150 ng/mL (varies by lab)
  • Below 12 ng/mL = definite iron deficiency
  • Below 30 ng/mL = strongly suggestive of iron deficiency in symptomatic patients
  • Iron deficiency can exist without anemia (ferritin low, hemoglobin still normal) - a very common scenario in young women

The Two Master Causes

According to Goldman-Cecil Medicine, the two fundamental mechanisms are:
  1. Increased iron loss (blood loss)
  2. Reduced iron absorption or intake

Circumstance 1 - Menstrual Blood Loss (Most Common Cause)

This is the #1 reason in women of reproductive age.
  • The average menstrual period causes loss of 35 mL of blood and 16 mg of iron
  • Women require 1-3 mg of iron/day, rising significantly with heavy periods
  • Heavy menstrual bleeding (>80 mL/cycle) - caused by fibroids, endometriosis, PCOS, or coagulation disorders - rapidly depletes stores
  • Studies show bone marrow iron stores are absent in 25% of healthy college-age women and reduced in another 33% - Goldman-Cecil Medicine
  • A JAMA study found nearly 40% of women ages 12-21 have low iron levels

Circumstance 2 - Inadequate Dietary Iron Intake

  • Vegetarian/vegan diet: Non-heme iron (from plants) is in the ferric (Fe³+) form, which absorbs far less efficiently than heme iron from meat. Lactovegetarians are at even higher risk - Goldman-Cecil Medicine
  • Calorie-restricted diets / disordered eating (common in young women)
  • Skipping meals, poor overall nutrition, reliance on processed foods low in iron
  • Iron-rich foods such as red meat, organ meats, legumes, and leafy greens are often under-consumed

Circumstance 3 - Poor Iron Absorption (Malabsorption)

Even with adequate intake, iron may not be absorbed properly:
ConditionMechanism
Celiac diseaseDuodenal villous atrophy impairs absorption; very common in young women
H. pylori infectionCauses achlorhydria (low stomach acid), reducing Fe³+ → Fe²+ conversion; also causes ulcer bleeding
Inflammatory bowel disease (Crohn's/UC)Mucosal damage + chronic GI blood loss
Autoimmune gastritisImpairs iron and later B12 absorption
Bariatric surgeryUp to 50% of post-bariatric patients become iron deficient
Proton pump inhibitors / antacidsReduce stomach acid needed for iron conversion

Circumstance 4 - Increased Iron Demand

The body's iron needs rise sharply in certain states:
  • Pregnancy: Requires ~900 mg total iron; about 6 mg/day in the third trimester (relevant even in young women)
  • Breastfeeding: Iron transfer to infant
  • Intense exercise / athletic training: Hemolysis from foot-strike, increased red cell turnover, sweat losses - a major cause in young female athletes

Circumstance 5 - GI Blood Loss (Non-menstrual)

  • Peptic ulcers / gastritis (especially from NSAIDs or H. pylori)
  • Hemorrhoids
  • Occult GI bleeding from any source

Circumstance 6 - Obesity / Elevated Hepcidin

  • Adipose tissue promotes chronic low-grade inflammation, raising hepcidin levels
  • Hepcidin degrades ferroportin, the iron export channel in the gut, thereby blocking iron absorption
  • About 8% of obese patients have elevated hepcidin as a marker of reduced iron absorption - Goldman-Cecil Medicine
  • A 2024 systematic review (PMID 39324337) confirmed the link between overweight/obesity and iron deficiency anaemia in reproductive-age women

Circumstance 7 - Hypothyroidism

  • Thyroid hormones are needed for normal stomach acid secretion and intestinal motility
  • Hypothyroidism (more common in young women) reduces hydrochloric acid production, impairing iron absorption
  • Fatigue from hypothyroidism can mimic or worsen iron deficiency symptoms

Circumstance 8 - Blood Donation

Frequent blood donors lose approximately 200-250 mg of iron per donation, quickly depleting stores in women who are already on the margin.

Symptoms of Low Ferritin (Even Without Anemia)

  • Fatigue and low energy (most common complaint)
  • Brain fog, poor concentration
  • Hair loss / thinning
  • Brittle nails, pale skin
  • Headaches, lightheadedness
  • Cold hands and feet
  • Restless leg syndrome
  • Reduced athletic performance
  • Shortness of breath on exertion

Summary Table

CategorySpecific Cause
Blood lossHeavy periods, GI bleeding, blood donation
DietVegetarian/vegan, calorie restriction, poor iron intake
MalabsorptionCeliac disease, H. pylori, IBD, low stomach acid, PPI use
Increased demandPregnancy, breastfeeding, intense exercise
Hormonal/metabolicHypothyroidism, obesity (elevated hepcidin)

Key point: In a 23-year-old woman, the combination of menstrual iron loss + a diet low in bioavailable iron accounts for the majority of cases. A ferritin level should always be checked alongside a full blood count, as iron deficiency without anemia is extremely common and frequently missed in this age group.
Sources: Goldman-Cecil Medicine (Iron Deficiency chapter), Tietz Textbook of Laboratory Medicine, Symptom to Diagnosis (4th Ed.), Franciscan Health, Nebraska Medicine

Tyroid 2.29 in same patient

Finding Sources
Finding Sources
Searching the Web

TSH 2.29 normal range interpretation young woman thyroid function

Here is a clear, complete interpretation of this result:

TSH = 2.29 mIU/L in a 23-Year-Old Woman

Verdict: NORMAL

A TSH of 2.29 mIU/L falls comfortably within the standard adult reference range of 0.4 - 4.0 mIU/L. The thyroid is functioning normally.

Where Does 2.29 Sit Exactly?

TSH ZoneRangeThis Patient
Hyperthyroid< 0.4 mIU/LNo
Normal (euthyroid)0.4 - 4.0 mIU/LYes - 2.29
Subclinical hypothyroid4.0 - 10 mIU/LNo
Overt hypothyroidism> 10 mIU/LNo
In fact, 2.29 is almost exactly the average TSH for a disease-free woman of this age group - a large population study found the mean TSH in young women to be around 2.24-2.29 mIU/L.

Does TSH 2.29 Explain Her Low Ferritin?

No. Since the thyroid is functioning normally, hypothyroidism is ruled out as a contributing factor to her low ferritin. You should focus on the other causes discussed previously:
  1. Menstrual blood loss (most likely)
  2. Dietary iron deficiency (vegetarian diet, poor intake)
  3. Malabsorption (celiac, H. pylori - worth checking)
  4. Increased demand (exercise, etc.)

One Important Note - Functional Medicine Perspective

Some functional/integrative practitioners use a narrower "optimal" TSH range of 1.0-2.0 mIU/L, and consider 2.1-2.9 as "borderline - monitor." Under this stricter view, 2.29 sits at the upper end of optimal. However, this is not standard medical practice and does not indicate any disease or treatment need. By all conventional guidelines, this patient is euthyroid.

What Should Be Done Next?

Since TSH is normal, the thyroid panel does not need further urgent investigation. The clinical priority for this patient should be:
  • Treat the low ferritin - oral iron supplementation (ferrous sulfate 150-200 mg elemental iron/day)
  • Investigate heavy menstrual bleeding if present
  • Check dietary history for iron intake
  • Consider celiac screen (tTG-IgA) if GI symptoms exist or ferritin remains low despite supplementation
  • Recheck ferritin in 3 months after supplementation
The TSH can be rechecked in 1-2 years as routine health maintenance, or sooner only if new thyroid symptoms develop.
This is a shared conversation. Sign in to Orris to start your own chat.